Company profile for Rapport Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Rapport Therapeutics aims to transform the treatment of neurological disorders through a precision medicine approach, precisely targeting disease-driving neurocircuits by leveraging receptor-associated proteins (RAPs). With this approach, Rapport can overcome the well-established limitations of today’s neuromedicines that act indiscriminately throughout the nervous system, resulting in suboptimal efficacy and burdensome side...
Rapport Therapeutics aims to transform the treatment of neurological disorders through a precision medicine approach, precisely targeting disease-driving neurocircuits by leveraging receptor-associated proteins (RAPs). With this approach, Rapport can overcome the well-established limitations of today’s neuromedicines that act indiscriminately throughout the nervous system, resulting in suboptimal efficacy and burdensome side effects. Leading the hunt for precision medicines is a team with established track records of innovation in neuroscience and drug discovery.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
201 Brookline Ave, Suite 1401 Boston, MA 02215
Telephone
Telephone
+1 8573218020
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

IPhEB Russia

Not Confirmed

envelop Contact Supplier

IPhEB Russia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2026/03/10/3252612/0/en/Rapport-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-Business-Update.html

GLOBENEWSWIRE
10 Mar 2026

https://www.globenewswire.com/news-release/2026/03/09/3251684/0/en/Rapport-Therapeutics-and-Tenacia-Biotechnology-Announce-Strategic-Collaboration-for-the-Development-and-Commercialization-of-RAP-219-in-Greater-China.html

GLOBENEWSWIRE
09 Mar 2026

https://www.fiercebiotech.com/biotech/tenacia-builds-308m-biobuck-deal-rapport-develop-epilepsy-drug-china

FIERCE BIOTECH
09 Mar 2026

https://www.globenewswire.com/news-release/2026/02/24/3244027/0/en/Rapport-Therapeutics-to-Participate-in-Upcoming-Investor-Conferences.html

GLOBENEWSWIRE
24 Feb 2026

https://www.globenewswire.com/news-release/2026/01/07/3214393/0/en/Rapport-Therapeutics-Announces-Accelerated-Initiation-of-RAP-219-Phase-3-Program-Expansion-of-Epilepsy-Portfolio-and-Continued-Progress-Across-the-Pipeline.html

GLOBENEWSWIRE
07 Jan 2026

https://www.globenewswire.com/news-release/2025/12/18/3207566/0/en/Rapport-Therapeutics-to-Present-at-the-44th-Annual-J-P-Morgan-Healthcare-Conference.html

GLOBENEWSWIRE
18 Dec 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty